US EditionAscletis Unveils ASC47 Weight Loss Drug Candidate
- The combination of ASC47 low dose with tirzepatide led to an 87% greater reduction in body weight in diet-induced obese mice compared to tirzepatide alone.
- ASC47 low dose combined with tirzepatide showed a statistically significant increase in efficacy over ASC47 with semaglutide, with reductions of 87% versus 55%.
- The combination treatment restored body composition in obese mice to that of healthy non-obese mice, with total muscle mass percentages of 60.4% for the treated mice and 62.0% for healthy mice.
- Upcoming topline data on ASC47 combined with semaglutide will guide future trials involving ASC47 with other incretin drugs, including tirzepatide.
Insights by Ground AI
Does this summary seem wrong?
58 Articles
58 Articles
Bennington Banner+56 Reposted by 56 other sources
Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, Demonstrated Greater Efficacy with Tirzepatide than Semaglutide in a Preclinical Model
The combination of ASC47 low dose with tirzepatide in diet-induced obese (DIO) mice resulted in an 87% greater reduction in body weight compared to tirzepatide monotherapy.
Ascletis Unveils ASC47 Weight Loss Drug Candidate
HONG KONG, Aug. 13, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces encouraging efficacy results from its study in diet-induced obese (DIO) mice combining ASC47, a first-in-class muscle-preserving weight loss drug candidate for the treatment of obesity, with tirzepatide. ASC47 is an adipose-targeted, once-monthly subcutaneously (SQ) injected thyroid hormone receptor beta (THRβ) selective small molecule agonist, discov…
Coverage Details
Total News Sources58
Leaning Left6Leaning Right9Center17Last UpdatedBias Distribution53% Center
Bias Distribution
- 53% of the sources are Center
53% Center
L 19%
C 53%
R 28%
Factuality
To view factuality data please Upgrade to Premium
